Humira (adalimumub) 40mg 2 syringes AbbVic, Germany

Indications. Rheumatoid arthritis (RA).

Humira in combination with methotrexate is indicated for:

• treatment of moderate to severe rheumatoid arthritis in adult patients when an adequate response to therapy with disease-modifying antirheumatic drugs (DMARDs), including methotrexate, has not been obtained;
• treatment of high-grade active progressive rheumatoid arthritis in adult patients who have not previously received methotrexate therapy.

Humira can be used as monotherapy in case of intolerance to methotrexate or when continuation of methotrexate therapy is unacceptable.

Humira demonstrated suppression of the progression of structural joint damage, which was confirmed radiographically, and improved functional status when used simultaneously with methotrexate.

Psoriatic arthritis (PSA). Humira is indicated for the treatment of active and progressive psoriatic arthritis in adults who have not responded adequately to prior disease-modifying antirheumatic drugs (DMARDs). Humira has been shown to slow down the rate of progression of peripheral joint injury, as measured by radiography, in patients with symmetrical polyarticular disease, and to improve functional status. Axial spondylitis Ankylosing spondylitis (AS).

Humira is indicated for the treatment of adult patients with highly active ankylosing spondylitis who have not responded adequately to conventional therapy.

Axial spondyloarthritis without radiological confirmation of AS.

Humira is indicated for the treatment of adult patients with highly active axial spondyloarthritis without radiographic evidence of AS, but with evidence of inflammation based on elevated CRP and/or MRI (magnetic resonance imaging).

Crohn's disease (CD).

Humira is indicated for the treatment of moderate to severely active Crohn's disease in adult patients who have not responded to a full course of corticosteroid and/or immunosuppressant therapy, or who have intolerance or medical contraindications to such

types of therapy.

Ulcerative colitis (UC).

Humira is indicated for the treatment of moderate to severe ulcerative colitis in adult patients who have not responded to conventional therapies, including corticosteroids and/or 6-mercaptopurine or azathioprine, or who have intolerance or medical contraindications to such therapies.

Plaque psoriasis (BP).

Humira is indicated for the treatment of adult patients with moderate to severe chronic plaque psoriasis who require systemic therapy.

Purulent hidradenitis (GG).

Humira is indicated for the treatment of active moderate to severe suppurative hidradenitis (acne inversa) in adult patients who have not responded to conventional systemic therapy.

Uveitis.

Humira is indicated for the treatment of noninfectious intermediary, posterior, and panuveitis in adult patients who have not responded to corticosteroid therapy, who need to reduce the dose of corticosteroid, or who have intolerance or medical contraindications to corticosteroid therapy.

In pediatrics

Juvenile rheumatoid (idiopathic) arthritis (JRA).

Polyarticular juvenile rheumatoid (idiopathic) arthritis

Humira in combination with methotrexate is indicated for the treatment of active polyarticular juvenile idiopathic arthritis in children 2 years of age and older who have not responded adequately to one or more disease-modifying antirheumatic drugs (DMARDs).

Humira can be used as monotherapy for methotrexate intolerance or when continuation of methotrexate therapy is unacceptable.

enthesitis-associated arthritis

Humira is indicated for the treatment of active enthesitis-associated arthritis in children aged 6 years and older who have not responded to conventional therapy, or who have an intolerance or medical contraindication to such therapies.

Crohn's disease (CD) in children.

Humira is indicated for the treatment of moderate to severely active Crohn's disease in children aged 6 years and older who have not responded to conventional therapies, including primary nutritional therapy, corticosteroid and/or immunomodulatory therapy, or who have intolerance or medical contraindications to such therapies.

Plaque psoriasis (PD) in children.

Humira is indicated for the treatment of severe chronic plaque psoriasis in children aged 4 years and older who have not received a clinical response or who have contraindications/intolerance to topical therapy or phototherapy.

300ole